Cipla EU picks up ~10.35% stake in Ethris, Germany for EUR 15 million

30 Dec 2022 , 09:26 AM

Cipla Limited announced that Cipla (EU) Limited, its wholly-owned UK subsidiary, has signed definitive agreements for an equity investment of EUR 15 million in Ethris GmbH (Ethris), a global leader in delivering mRNAs directly to the respiratory system, including administration via inhalation.

The investment will enable a long-term strategic partnership between Cipla and Ethris for the development of messenger RNA (mRNA)-based therapies, as well as accelerate Cipla’s participation in the mRNA space. This will allow Cipla to provide developing countries with access to cutting-edge solutions developed by Ethris.

“Cipla EU will invest EUR 15 million to acquire 9,939 common shares with a face value of EUR 1 each, representing a 10.35% stake in Ethris’ registered share capital,” said the company in its exchange filing on Thursday.

A collaboration agreement is signed concurrently with the definitive agreement, paving the way for Ethris’ innovative portfolio to be marketed in Cipla’s key emerging markets.

The transaction is expected to be completed within 60 days of the agreement’s signing date, or within such other time period as the parties mutually agree in writing, and is subject to the completion of necessary regulatory formalities.

For feedback and suggestions, write to us at [e-mail]